Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER

An independent Safety Review Committee (SRC), supported by Novartis Pharma AG, analyzed investigator-reported cases of intraocular inflammation (IOI), endophthalmitis, and retinal arterial occlusion in the phase 3 HAWK and HARRIER trials of brolucizumab versus aflibercept in neovascular age-related...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Jg. 128; H. 7; S. 1050
Hauptverfasser:	Monés, Jordi, Srivastava, Sunil K, Jaffe, Glenn J, Tadayoni, Ramin, Albini, Thomas A, Kaiser, Peter K, Holz, Frank G, Korobelnik, Jean-Francois, Kim, Ivana K, Pruente, Christian, Murray, Timothy G, Heier, Jeffrey S
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.07.2021
Schlagworte:	neovascular age-related macular degeneration intraocular inflammation safety brolucizumab retinal vasculitis retinal arterial occlusion retinal occlusive vasculitis retinal vascular occlusion
ISSN:	1549-4713, 1549-4713
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!